港股科网板块回调，医药、消费走强

Group 1 - The Hang Seng Index opened down 0.5%, with the Hang Seng Tech Index falling 0.82%, while pharmaceutical stocks rebounded, particularly Innovent Biologics, which surged nearly 10% after a global strategic partnership with Takeda Pharmaceutical [1] - Pop Mart opened nearly 8% higher, reporting a year-on-year revenue increase of 245%-250% for the third quarter [1] - Amid global uncertainty, there is an increased demand for scarce and certain assets, leading to a rise in safety requirements [1] Group 2 - Following previous plans to increase defense spending in Europe, there is support for expanded defense budgets, which may accelerate global capital expenditures and increase demand for capital goods [1] - Since the beginning of the year, global funds over-allocated to the dollar have started to diversify or return, reflected in an 8.8% decline in the dollar index against major currencies [1] - From September, developed markets have underperformed emerging markets, with MSCI developed markets rising 0.6% and MSCI emerging markets rising 2.2% during the October holiday [1] Group 3 - Hong Kong's stock market has become a core platform for international capital to diversify dollar asset allocations, with its correlation to the US market rapidly decreasing since 2018, reaching about 12% by the end of September [2] - The Hong Kong stock market has gathered core domestic AI assets across the entire industry chain, becoming a pioneer in the revaluation of Chinese assets [2] - Although there has been a short-term adjustment in the Hong Kong stock market, the upward trend remains intact, and the market is expected to benefit significantly from the onset of a Federal Reserve rate cut cycle [2] Group 4 - Relevant ETFs include the Hong Kong Stock Connect Technology ETF (159101), Hang Seng Internet ETF (513330), Hong Kong Consumption ETF (513230), and Hang Seng Pharmaceutical ETF (159892) [3]